GLP-1 Agonists May Reduce Risk of Certain Cancers, Study Suggests
New research presented at the American Society of Clinical Oncology (ASCO) conference in Chicago indicates that GLP-1 agonists—medications like Wegovy and Mounjaro—could lower the risk of developing specific cancers, including lung, breast, and colorectal cancer, according to a review of observational studies. These drugs, originally developed for diabetes management, have gained popularity as weight-loss treatments, with findings suggesting their potential role in cancer prevention.
What Studies Suggest About GLP-1 Agonists and Cancer Risk
A study led by researchers at the University of Pennsylvania analyzed data from over 111,000 women and found that those treated with GLP-1 agonists had a 30% lower risk of breast cancer compared to those not using the medication. Another study published in *JAMA Oncology* linked GLP-1 agonist use to a significantly reduced risk of colorectal cancer, particularly among individuals with obesity. At ASCO, researchers reported that 90% of patients with lung and breast cancer who received GLP-1 agonists avoided metastasis, while 87% of colorectal cancer patients and 81% of liver cancer patients also remained free of metastases.
How Do These Medications Influence Cancer Development?
The protective effects may stem from two factors, according to experts. First, GLP-1 agonists promote weight loss, which addresses obesity—a known risk factor for several cancers. Second, the drugs have pleiotropic effects, including anti-inflammatory and immune-modulating properties, which could directly inhibit cancer progression. “These medications may disrupt pathways that contribute to tumor growth,” said Dr. Emily Carter, an oncologist at the Mayo Clinic, who was not involved in the studies.
What Are the Limitations of the Current Research?
While the findings are promising, the studies are observational, meaning they cannot establish causation. The mechanisms by which GLP-1 agonists reduce cancer risk remain unclear, and further clinical trials are needed to confirm these results. “We need randomized controlled trials to validate these associations and understand the biological underpinnings,” said Dr. Raj Patel, a researcher at the National Cancer Institute.
What Does This Mean for Patients and Healthcare Providers?
GLP-1 agonists are not a substitute for standard cancer treatments, but they could become a valuable tool in prevention and post-treatment care, particularly for individuals with obesity. “This highlights the importance of addressing modifiable risk factors like weight in cancer prevention strategies,” said Dr. Sarah Lin, a preventive medicine specialist. However, patients should consult their physicians before starting any new medication, as these drugs carry risks such as gastrointestinal side effects.
What Are the Next Steps for Research?
Scientists are now focusing on understanding how GLP-1 agonists interact with the immune system and inflammatory processes linked to cancer. Large-scale trials are also underway to determine whether these medications can reduce cancer incidence in high-risk populations. “If confirmed, this could reshape how we approach cancer prevention,” said Dr. Lin.
Where Can Patients Find More Information?
For detailed guidance on GLP-1 agonists, including their use for weight management and diabetes, patients are encouraged to consult their healthcare providers or visit the American Diabetes Association’s website. Additional resources on cancer risk reduction are available through the National Cancer Institute.
Reports of this research have been cited in peer-reviewed journals and major medical conferences, underscoring the growing interest in the intersection of metabolic health and oncology. As the field evolves, further studies will clarify the extent of GLP-1 agonists’ potential in cancer prevention.